Nicholas A. Kartsonis
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Antifungal resistance and susceptibility, Fungal Infections and Studies, Antimicrobial Resistance in Staphylococcus, Cystic Fibrosis Research Advances, Antibiotics Pharmacokinetics and Efficacy
Most-Cited Works
- → Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis(2002)1,382 cited
- → Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation(2017)1,163 cited
- → Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection(2017)834 cited
- → Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy(2004)660 cited
- → RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections(2019)385 cited
- → Effect of an Investigational Vaccine for Preventing Staphylococcus aureus Infections After Cardiothoracic Surgery(2013)360 cited
- → A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis(2002)291 cited
- → Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents(2005)239 cited
- → A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)(2020)215 cited
- → A Multicenter, Double‐Blind Trial of a High‐Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis(2009)213 cited